Naloxon Inresa (Naloxone Hydrochloride Dihydrate)

Naloxone, the active ingredient in Naloxon Inresa, is an opioid antagonist presented as a sterile injectable solution for intramuscular and intravenous use. It rapidly reverses the effects of opioid overdose and opioid‑induced respiratory depression in emergency settings. GNH USA supplies Naloxon Inresa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naloxone is an opioid antagonist used in emergency medicine to counteract opioid toxicity. - Opioid overdose: restores normal breathing and consciousness in patients with life‑threatening opioid intoxication. - Opioid‑induced respiratory depression: rapidly reverses slowed or stopped breathing caused by opioid administration. - Acute opioid toxicity: mitigates severe central nervous system depression and circulatory collapse due to opioid exposure.

Naloxone may cause a range of adverse reactions, most of which are related to its rapid reversal of opioid effects.

Common Side Effects: - Nausea - Vomiting - Sweating - Headache - Dizziness - Injection site pain

Serious or Rare Side Effects: - Hypertension - Cardiac arrest - Seizures - Anaphylaxis - Pulmonary edema - Arrhythmias

Naloxone should be administered with careful clinical assessment and monitoring. - Assess respiratory status: confirm depressed breathing before administration. - Verify opioid involvement: ensure opioid exposure is the likely cause. - Hypersensitivity: avoid in patients with known allergy to naloxone or formulation components. - Cardiovascular disease: use cautiously in patients with unstable heart conditions. - Acute withdrawal: monitor for signs of sudden opioid withdrawal, especially in dependent individuals. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Naloxone may interact with other drugs that affect the central nervous system or opioid pathways.

Major Interactions (Avoid): - Potent opioid agonists: concurrent use may reduce naloxone’s ability to reverse overdose. - Mixed agonist‑antagonist opioids (e.g., buprenorphine): can precipitate severe withdrawal.

Moderate Interactions (Monitor Closely): - Sedatives (benzodiazepines, barbiturates): respiratory depression may persist despite naloxone. - Monoamine oxidase inhibitors: increased risk of hypertensive events. - Adrenergic agents (e.g., epinephrine): may exacerbate hypertension after naloxone administration.